Common Pharmaceutical: Plans to engage in foreign exchange derivatives trading business with a limit of no more than RMB 300 million.

Gongtong Pharmaceutical announced that the company and its subsidiaries plan to conduct foreign exchange derivatives trading business with financial institutions qualified to operate foreign exchange derivatives trading. The total transaction amount shall not exceed RMB 300 million, and the upper limit of transaction margin and premium shall not exceed RMB 10 million. The quota can be recycled within 12 months from the date of approval by the board of directors. The transactions are for hedging purposes and do not involve speculative arbitrage. This matter has been reviewed and approved at the 16th meeting of the third board of directors of the company and does not need to be submitted to the shareholders' meeting for review.